Sec. 7. Studies and reports
200 words·~1 min read·
/bill/116/hr/8920/ih/section-7·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Not later than 6 years after the date of enactment of this Act, the Comptroller General of the United States shall complete a study on the effectiveness of this Act in developing priority antimicrobial drugs. Such study shall examine the indications for, usage of, development of resistance with respect to, and private and societal value of critical need antimicrobial drugs, and the impact of the programs under this Act on patients and markets of critical need antimicrobial drugs.
The Comptroller General shall report to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives on the findings of such study. The Director of the Centers for Disease Control and Prevention shall, each year, update the report entitled Antibiotic Use in the United States to include updated information on progress and opportunities with respect to data, programs, and resources for prescribers to promote appropriate use of antimicrobial drugs.
Not later than 3 years after the date of enactment of this Act, the Director of the Centers for Disease Control and Prevention shall publish— a report on antifungal resistance in the United States; and a report on antimicrobial prophylactics.